Key Points
The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India's Covid-19 shots...
The University of Oxford said on Thursday it had begun human testing of an experimental vaccine against the brain-swelling Nipah virus that led to outbreaks in India's Kerala state and other parts of Asia...
The 51-patient early-stage trial will take place in Oxford and will examine the safety and immune response of the vaccine in people aged 18 to 55 years, a spokesperson for the University's Pandemic Sciences Institute said...
The trial is led by Oxford Vaccine Group and funded by CEPI, a global coalition that supports the development of vaccines against emerging infectious diseases...
Moderna (MRNA.O) in 2022 also started an early-stage clinical trial of a Nipah virus vaccine, which it co-developed with the U.S.' National Institute of Allergy and Infectious Diseases...
You might be interested in
Serum Institute statement on Covishield as AstraZeneca withdraws vaccine
08, May, 24Serum Institute of India said that the firm stopped manufacturing and supply of additional doses of Covishield since December 2021 as demand for the shot diminished.
India’s cervical cancer drug, Cervavac, as efficient as global medicines: Lancet
31, Dec, 23Cervical cancer accounts for the second-highest number of cancer cases in India among women, after breast cancer. Serum Institute of India rolled out Cervavac earlier this year
Biological E's Covid-19 vaccine CORBEVAX gets WHO emergency use listing
16, Jan, 24India Business News: Biological E's Covid-19 vaccine CORBEVAX has received emergency use listing from the World Health Organisation (WHO). The vaccine was approved in India for restricted use in emergency for adults, adolescents, and young children, as well as a heterologous booster dose for those aged 18 years and above. The Hyderabad-based vaccine maker has already supplied 100 million doses of CORBEVAX to the Indian government. The WHO EUL will help the company continue developing Covid-19 vaccines.
First human trial for deadly Nipah virus vaccine begins in UK
16, Jan, 24Nipah virus is a devastating disease that can be fatal in around 75 per cent of cases.. Scientists at the University of Oxford in the UK have launched the...
The Vial: SII CEO Adar Poonawalla on making Covidshied: 'It was a sense of responsibility of lives & livelihoods'-Entertainment News , Firstpost
24, Mar, 23Serum Institute collaborated with Oxford University and AstraZeneca to make Covidshield.